RF
PVLA

Rossby Financial’s Palvella Therapeutics PVLA Stock Holding History

Rossby Financial’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67K Sell
24
-1
-4% -$121 ﹤0.01% 1556
2026
Q1 		$3.01K Buy
+25
New +$2.61K ﹤0.01% 1678

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Rossby Financial's PVLA Position: Q2 2026 in Review

Rossby Financial reduced its Palvella Therapeutics (PVLA) stake by 4% in Q2 2026, selling an estimated $121 and leaving 24 shares worth $3.67K. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Rossby Financial first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Rossby Financial held 24 shares of Palvella Therapeutics worth $3.67K as of Q2 2026.
  • Rossby Financial sold 1 Palvella Therapeutics share in Q2 2026, an estimated $121.
  • Palvella Therapeutics made up ﹤0.01% of Rossby Financial's portfolio in Q2 2026, its #1556 holding.
  • Rossby Financial first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Rossby Financial's 13F filing for Q2 2026, filed 4 Aug 2026.